plozasiran sodium

all catalysts(1)

News(7)

• Arrowhead's new Redemplo findings in severe hypertriglyceridemia have analysts split
  Safety and dosing are likely to be “key differentiators” for Arrowhead Pharmaceuticals as it looks to challenge Ionis Pharmaceuticals’ lead in the severe hypertriglyceridemia market.
  biospace · 1mo ago
• #ESC26: Arrowhead claims safety edge over Ionis as triglyceride battle draws closer
  MUNICH — Arrowhead is on course to crash Ionis Pharmaceuticals’ party. Arrowhead’s RNA interference drug Redemplo looked safer as well as effective in two late-stage trials in patients with high le…
  endpoints · 1mo ago
• ‘Significant’ demand for Revolution drug; Intellia pinpoints liver toxicity culprit
  Early indicators from a compassionate use plan led analysts to hike projections for daraxonrasib. Elsewhere, Intellia believes it’s answered a key safety question and Arrowhead moved to catch a rival.
  biopharma_dive · 1mo ago
• FDA panel confronting peptide controversy
  Today's biotech news features the FDA weighing the fate of peptides; approvals for RevMed, GSK; and data on Lilly's "triple-G."
  stat · 2mo ago
• Arrowhead hits ‘best-case scenario’ with latest results for fat-lowering drug
  To analysts, the drug’s apparent safety and effects on both triglyceride levels and pancreatitis cases should make it competitive with a rival Ionis therapy.
  biopharma_dive · 2mo ago
• Arrowhead’s gene silencer competitive with Ionis’ in triglyceride disease
  Arrowhead Pharmaceuticals’ lipid-lowering drug has hit in two late-stage trials that could expand its use into a much wider population. Data shared Wednesday showed that Arrowhead’s gene silencer R…
  endpoints · 2mo ago
• Arrowhead puts pressure on Ionis with positive data for triglyceride lowering drug
  With Phase 3 data showing what analysts called a “potentially best-in-class profile,” Arrowhead Pharmaceuticals plans to submit for FDA approval of plozasiran by the end of the year—hoping to follo…
  biospace · 2mo ago